Life Sciences

  • May 08, 2026

    Ex-FDA Chief Says J&J Atty 'Spinning' Asbestos Definition

    A former U.S. Food and Drug Administration commissioner told an attorney for Johnson & Johnson she was "spinning" the definition of asbestos in an attempt to confuse a jury in a bellwether trial over claims the company's talc products caused three women's deaths from ovarian cancer.

  • May 08, 2026

    FTC's Gender-Care Probe Likely Retaliatory, Judge Says

    The Endocrine Society has convinced a D.C. federal judge that the Federal Trade Commission's motivation for targeting it with a subpoena was likely retaliation for the guidelines the nonprofit produced regarding gender-affirming care.

  • May 08, 2026

    10x, Curio Settle Genomics Patent Suit Before Trial

    10x Genomics on Friday said it has agreed to end its suit accusing Curio Bioscience of infringing a series of Prognosys Biosciences genomics technology patents that 10x Genomics is licensed to use.

  • May 08, 2026

    Sports Tech Co. Says Judge Made Own Patent Eligibility Case

    Finnish sports tech company Polar Electro has asked the U.S. Supreme Court to revive its infringement case against a rival over a heart monitoring patent, saying a district judge made up his own case for patent eligibility when he ruled the patent was invalid.

  • May 08, 2026

    10x, Harvard Sue Sequencing Co. Over Biology Patents

    10x Genomics Inc. and Harvard have sued Element Biosciences Inc. in Delaware federal court, accusing the San Diego sequencing company of infringing four Harvard-owned patents through Element's AVITI24 platform and related Teton chemistry.

  • May 08, 2026

    Ex-Wachtell Lipton Atty Tied To Stolen BigLaw Info Trades

    A former Wachtell Lipton Rosen & Katz attorney who later worked for investment bank LionTree LLC is an unindicted co-conspirator in a sweeping alleged insider trading scheme that involved stolen information from several prominent law firms, according to a review of publicly available information.

  • May 08, 2026

    Covington, Cooley Lead Drugmaker Odyssey's $279M IPO

    Venture-backed biotechnology firm Odyssey Therapeutics began trading publicly Friday after raising $279 million in its initial public offering, making it the latest biotech to hit the public markets over the last few weeks.

  • May 08, 2026

    Squires Says Yes To 7 Patent Petitions, No To A Dozen More

    U.S. Patent and Trademark Office Director John Squires granted seven petitions for patent review under the America Invents Act and denied 12 other petitions, including a host of challenges by Cisco Systems and Samsung Electronics.

  • May 08, 2026

    Don't Miss It: Paul Hastings, V&E Steer Latest Hot Deals

    A lot can happen in the world of mergers and acquisitions and equity fundraising over the course of a couple weeks, and it's difficult to keep up with all the deals.

  • May 08, 2026

    Catalent Agrees To Pay $78M To Settle Securities Suit

    Catalent Inc. agreed on Thursday to pay $78 million to settle a securities class action from a group of investors who alleged the vaccine manufacturer engaged in accounting and channel stuffing schemes and cut corners on safety to pad its revenues.

  • May 08, 2026

    Walgreens Loses Atty Sanctions Bid In Georgia Bias Suit

    The attorney for a former pharmacist suing Walgreens for discrimination has escaped a sanctions bid after a Georgia federal judge found the chain gave the lawyer too little time to respond to a motion to dismiss claims.

  • May 08, 2026

    Cardiac Device Co. Says Ex-Manager Took Secrets To Rival

    Vital Connect Inc., a company that sells wearable cardiac monitoring devices, told a North Carolina federal court that a former senior key accounts manager pilfered its confidential information only to decamp to a competitor and begin soliciting its clients.

  • May 08, 2026

    Squires Says Fitness Tracker Patent Date Key To PGR Ruling

    Wearable technology company Whoop Inc. has shown that an Omni Medsci Inc. patent can be challenged under the America Invents Act because its effective filing was after a cutoff date in the law, U.S. Patent and Trademark Office Director John Squires has found.

  • May 07, 2026

    Fed. Circ. Judges Stuck On Drug Efficacy's Role In Patents

    A Federal Circuit panel struggled Thursday to pin down where the line is between patent enablement on cancer drug patents and U.S. Food and Drug Administration standards, as a Pfizer unit tried to revive its $107 million jury victory over AstraZeneca.

  • May 07, 2026

    J&J Feared FDA's 'Disturbing Proposal' To Test Talc, Jury Told

    A former U.S. Food and Drug Administration commissioner testifying Thursday in a Los Angeles bellwether trial over claims Johnson & Johnson's talc products caused three women's deadly ovarian cancer described an internal document showing J&J feared the FDA's "disturbing proposal" to test the talc instead of relying on industry self-testing.

  • May 07, 2026

    La. Says Mailed Abortion Pills Harm State Budget, Sovereignty

    The state of Louisiana on Thursday defended its standing to challenge telehealth access to the abortion medication mifepristone, telling the U.S. Supreme Court that it has suffered financial and other injuries as mail-order pills flood the state.

  • May 07, 2026

    Judge, In 'Difficult Position,' OKs Rare Patent Defense

    A Massachusetts federal judge found himself in what he said was a "difficult position" in allowing an unusual defense to be advanced in a patent infringement case related to blood pumps in light of criticism of the defense from the Federal Circuit.

  • May 07, 2026

    $495M Win Upheld In Abbott Baby Formula Bellwether Trial

    A Missouri appellate panel on Tuesday upheld a trial win of $95 million in compensatory damages and $400 million in punitive damages over bellwether claims that Abbott Laboratories' baby formula caused a premature baby to suffer a fully disabling condition.

  • May 07, 2026

    Bayer Sued Over Healthy Sperm Claim On 'One A Day' Pill

    Bayer AG has been hit with a proposed class action in New York federal court alleging that claims on its Men's One A Day Pre-Conception Health Multivitamin supplements misleadingly convey that they could improve chances of conception and support sperm health.

  • May 07, 2026

    Bayer Loses Bid To Undo Class In 'One A Day' Label Suit

    A New York federal judge on Wednesday declined to decertify a class action alleging that Bayer's "One A Day" gummy vitamins deceive consumers about serving sizes, allowing the case to continue since there's evidence that a significant number of consumers could be confused.

  • May 07, 2026

    Liberty Left Client Info Vulnerable To Hackers, Suit Alleges

    Liberty Mutual Insurance Co. faces a proposed consumer class action alleging it failed to effectively safeguard private information for current and former clients after hackers claimed they stole information and sought a ransom payment.

  • May 07, 2026

    Judge Knocks Out Pfizer Partner's Vax Case Against GSK

    A Delaware federal judge on Thursday threw out a suit seeking a finding that a drug developer that partnered with Pfizer and BioNTech on their COVID-19 vaccine didn't infringe drugmaker GlaxoSmithKline's patents.

  • May 07, 2026

    Pharma Cos. Hit With $2M Judgment Over CBD Investor Fraud

    A California federal judge has issued final judgments against a pharmaceutical company, its CEO and an affiliate on claims from the U.S. Securities and Exchange Commission that they defrauded investors of $6.6 million, hitting them with more than $2 million in damages and civil penalties.

  • May 07, 2026

    AstraZeneca Reps Fight To Keep Opt-Ins In Pay Bias Suit

    Female pharmaceutical sales representatives in an AstraZeneca equal pay suit have urged an Illinois federal court to reject the company's bid to dismiss two dozen opt-in plaintiffs for refusing discovery, saying the women feared retaliation and career consequences.

  • May 07, 2026

    Ex‑Novartis Atty Wins Revival Of Whistleblower Claims

    The New Jersey state appeals court on Thursday revived five whistleblower claims brought by a former Novartis compliance attorney, finding that a trial judge wrongly treated a years‑long pattern of alleged retaliation as discrete, time‑barred events rather than a continuous campaign culminating in her 2021 termination.

Expert Analysis

  • How 10 Years Of Case Law Have Shaped The DTSA

    Author Photo

    As the Defend Trade Secrets Act reaches its 10th anniversary, attorneys at Ropes & Gray examine recent DTSA case law and highlight key takeaways regarding pleading requirements, damages and risk factors.

  • The Ethics And Practicalities Of Representing AI Agents

    Author Photo

    With autonomous artificial intelligence agents now able to take action without explicit instructions from — or the awareness of — their human owners, the bar must confront whether existing frameworks like informed consent and client privilege will be sufficient on the day an AI agent calls seeking counsel, say attorneys at Morrison Cohen.

  • Series

    Speed Jigsaw Puzzling Makes Me A Better Lawyer

    Author Photo

    My passion for speed puzzling — I can complete a 500-piece jigsaw puzzle in under 50 minutes — has sharpened my legal skills in more ways than one, with both disciplines requiring patience, precision and the ability to keep the bigger picture in mind while working through the details, says Tazia Statucki at Proskauer.

  • Opinion

    Congress Should Ax Privacy Bill For Not Shielding Consumers

    Author Photo

    The SECURE Data Act should be rejected because, despite Congress' claims, it would not meaningfully rein in data practices, but instead would weaken enforcement, eliminate stronger protections and prioritize data extraction over consumer protection and accountability, say attorneys at DiCello Levitt.

  • Suit's Dismissal Would Not Settle Gold Card Visa's Legality

    Author Photo

    The government’s recent assertion that the plaintiffs in American Association of University Professors v. Department of Homeland Security lack standing to challenge the Trump administration’s pay-to-play immigration program does not address whether an agency can deem a million-dollar gift evidence of eligibility for immigration benefits carefully defined by Congress, says Jun Li at Reid & Wise.

  • 2 AI Snafus Show Why Attys Can't Outsource Judgment

    Author Photo

    The recent incident involving Sullivan & Cromwell where citations in a filed motion were fabricated by artificial intelligence, as well as a punitive ruling from the Sixth Circuit in U.S. v. Farris, demonstrate that the obligation to supervise AI has belonged and always will belong to lawyers, says John Powell at the Kentucky School Boards Association.

  • Opinion

    Congress Must Repair USPTO's Inter Partes Review Process

    Author Photo

    To challenge recent changes to the inter partes review process issued by the U.S. Patent and Trademark Office, Congress must establish clear statutory guardrails, transparency and meaningful judicial review so that questionable patents receive proper scrutiny, say Sean Tu at the University of Alabama, Arti Rai at Duke University and Aaron Kesselheim at Harvard.

  • Previewing FDA Preapproval Access In Psychedelics EO

    Author Photo

    The second of two pathways for psychedelic drug access outlined in President Donald Trump's recent executive order constitutes an unprecedented expansion of the Right to Try Act, which could fundamentally alter the psychedelic access landscape while presenting significant regulatory, operational and legal challenges, say attorneys at Husch Blackwell.

  • NY's Growing Enviro Reg Framework Will Transform Projects

    Author Photo

    Three closely connected environmental rulemakings in New York state — concerning greenhouse gas reporting, remediation standards and amendments to the State Environmental Quality Review Act — have reached critical stages, and taken together, they will have major impacts on business operations, construction project timelines and transactional risk, say attorneys at Holland & Knight.

  • How 'Spillover' Effects Can Skew AI Securities Class Actions

    Author Photo

    Event study evidence is often central in securities litigation at class certification and beyond, but in an environment where earnings forecasts and statements can have spillover market implications, particularly when concerning artificial intelligence, the task of parsing out the price impact of news requires careful consideration, say Erik Johannesson, Olivia Wurgaft and Nguyet Nguyen at Brattle Group.

  • Previewing FDA National Priority Vouchers In Psychedelics EO

    Author Photo

    President Donald Trump's recent executive order on psychedelic drug access represents a watershed moment in federal drug policy, but its significance lies in two distinct regulatory pathways, the first being the Commissioner's National Priority Vouchers, which offer a significant opportunity to compress U.S. Food and Drug Administration review, say Kimberly Chew at Husch Blackwell and Odette Hauke at Odette Alina.

  • Series

    Playing Magic: The Gathering Makes Me A Better Lawyer

    Author Photo

    The competitive card game Magic: The Gathering offers me a training ground for the strategic thinking skills crucial to litigation, challenging me to adapt to oft-updated rules, analyze text as complicated as any statute and anticipate my opponent’s next moves, says Christopher Smith at Lash Goldberg.

  • Why Product-Based Public Nuisance Claims May Be Waning

    Author Photo

    The Maryland Supreme Court's recent decision in Express Scripts v. Anne Arundel County is the latest in a national trend of rulings rejecting product-based public nuisance claims — but other forms of government litigation against companies that allegedly increase the cost of public services are likely to continue, say attorneys at Simpson Thacher.

  • Improving Well-Being In Law, 10 Years After Landmark Study

    Author Photo

    An important 2016 study revealed significant substance abuse and mental health issues among lawyers, and while the findings helped normalize the conversation around these topics, a decade later, structural change is still needed, says Denise Robinson at PLI.

  • How To Gear Up For Trump's Pharma Tariffs

    Author Photo

    President Donald Trump's proclamation establishing tariffs on certain pharmaceutical products holds a few areas of ambiguity that companies should review and prepare for before the tariffs come into effect later this year, say attorneys at Arnold & Porter.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here